Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma

Autor: Keller, Kaylee M., Eleveld, Thomas F., Schild, Linda, van den Handel, Kim, van den Boogaard, Marlinde, Amo-Addae, Vicky, Eising, Selma, Ober, Kimberley, Koopmans, Bianca, Looijenga, Leendert, Tytgat, Godelieve A.M., Ylstra, Bauke, Molenaar, Jan J., Dolman, M. Emmy M., van Hooff, Sander R., Afd Pharmaceutics, Pharmaceutics

Publikováno v: Frontiers in Oncology, 12, 1. Frontiers Media S.A.
Frontiers in Oncology, 12:929123. Frontiers Media S.A.
Frontiers in oncology, 12:929123. Frontiers Media S.A.
Keller, K M, Eleveld, T F, Schild, L, van den Handel, K, van den Boogaard, M, Amo-Addae, V, Eising, S, Ober, K, Koopmans, B, Looijenga, L, Tytgat, G A M, Ylstra, B, Molenaar, J J, Dolman, M E M & van Hooff, S R 2022, ' Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma ', Frontiers in Oncology, vol. 12, 929123 . https://doi.org/10.3389/fonc.2022.929123

Neuroblastoma is the most common extracranial solid tumor found in children and despite intense multi-modal therapeutic approaches, low overall survival rates of high-risk patients persist. Tumors with heterozygous loss of chromosome 11q and MYCN amp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::329aea7d7c7654768bccaddc20ad5c25
https://dspace.library.uu.nl/handle/1874/425877

αβ-T Cells Engineered to Express γδ-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression

Autor: Strijker, Josephine G M, Pscheid, Ronja, Drent, Esther, van der Hoek, Jessica J F, Koopmans, Bianca, Ober, Kimberley, van Hooff, Sander R, Kholosy, Waleed M, Cornel, Annelisa M, Coomans, Chris, Bisso, Andrea, van Loenen, Marleen M, Molenaar, Jan J, Wienke, Judith, Afd Pharmaceutics, Pharmaceutics

Publikováno v: Journal of Personalized Medicine, 11(9):923. MDPI Multidisciplinary Digital Publishing Institute
Journal of Personalized Medicine
Volume 11
Issue 9
Journal of Personalized Medicine, 11(9), 1. Multidisciplinary Digital Publishing Institute (MDPI)
Journal of Personalized Medicine, Vol 11, Iss 923, p 923 (2021)

Currently ~50% of patients with a diagnosis of high-risk neuroblastoma will not survive due to relapsing or refractory disease. Recent innovations in immunotherapy for solid tumors are highly promising, but the low MHC-I expression of neuroblastoma r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5758e9e2b160808f1a7ecbbc74004a7
https://pure.amc.nl/en/publications/t-cells-engineered-to-express-t-cell-receptors-can-kill-neuroblastoma-organoids-independent-of-mhci-expression(2a6b190d-9b38-4b31-86ec-ddf3fa05033d).html